U.S. missile stockpiles dwindle. And, FDA weighs approval of flu shots with mRNA tech

The U.S. Army's missile stockpile is dwindling and could take years to replenish. And, the Food and Drug Administration is deciding whether to approve a flu vaccine with mRNA technology.

<img src='undefined' alt='A U.S.-made MIM-104 Patriot surface-to-air missile is launched during a live fire exercise at the Chiupeng missile base in Pingtung County on Aug. 20, 2024.'/><p>The U.S. Army's missile stockpile is dwindling and could take years to replenish. And, the Food and Drug Administration is deciding whether to approve a flu vaccine with mRNA technology.</p><p>(Image credit: Sam Yeh)</p><img src='https://media.npr.org/include/images/tracking/npr-rss-pixel.png?story=g-s1-137429' />